Premium
MOZ/TIF2‐induced acute myeloid leukaemia in transgenic fish
Author(s) -
Zhuravleva Julia,
Paggetti Jérôme,
Martin Laurent,
Hammann Arlette,
Solary Eric,
Bastie JeanNoël,
Delva Laurent
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07362.x
Subject(s) - fusion gene , biology , transgene , cancer research , myeloid , zebrafish , gene , microbiology and biotechnology , genetics
Summary The inv(8)(p11q13) chromosomal abnormality, described in acute myeloid leukaemias (AML), fuses the histone acetyl‐transferase (HAT) MYST3 ( MOZ) gene with another HAT gene, NCOA2 ( TIF2 ). We generated a transgenic zebrafish in which the MYST3/NCOA2 fusion gene was expressed under control of the spi1 promoter. An AML developed in 2 of 180 MYST3/NCOA2‐EGFP‐expressing embryos, 14 and 26 months after injection of the fusion gene in a one‐cell embryo, respectively. This leukaemia was characterised by an extensive invasion of kidneys by myeloid blast cells. This model, which is the first zebrafish model of AML, demonstrates the oncogenic potency of MYST3/NCOA2 fusion gene.